Recombinant insulin aspart biosimilar (Biogenomics)
门冬胰岛素生物类似药 (Biogenomics)
Report date: 2025/02/19 16:42:45
Base Information
Drug NameRecombinant insulin aspart biosimilar (Biogenomics)
Drug Alias Name
Classification
Mechanisms of Action
Targets
Therapy Area/Indications
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/Territory
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaN/A
Originator CompaniesBiogenomics
China Registration ClassN/A
Develop Information
Other Information
ATC Code
Related LinksN/A